North America Hemato Oncology Testing Market Size & Outlook

The hemato oncology testing market in North America is expected to reach a projected revenue of US$ 2,516.4 million by 2028. A compound annual growth rate of 14.6% is expected of North America hemato oncology testing market from 2021 to 2028.
Revenue, 2020 (US$M)
$848.4
Forecast, 2028 (US$M)
$2,516.4
CAGR, 2021 - 2028
14.6%
Report Coverage
North America

North America hemato oncology testing market highlights

  • The North America hemato oncology testing market generated a revenue of USD 848.4 million in 2020.
  • The market is expected to grow at a CAGR of 14.6% from 2021 to 2028.
  • In terms of segment, lymphoma was the largest revenue generating cancer type in 2020.
  • Lymphoma is the most lucrative cancer type segment registering the fastest growth during the forecast period.
  • Country-wise, Canada is expected to register the highest CAGR from 2021 to 2028.


North America data book summary

Market revenue in 2020USD 848.4 million
Market revenue in 2028USD 2,516.4 million
Growth rate14.6% (CAGR from 2020 to 2028)
Largest segmentLymphoma
Fastest growing segmentLymphoma
Historical data covered2018 - 2019
Base year for estimation2020
Forecast period covered2021 - 2028
Quantitative unitsRevenue in USD million
Market segmentationLeukemia, Lymphoma, MPNs, Other Cancers
Key market players worldwideRoche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp


Other key industry trends

  • In terms of revenue, North America region accounted for 36.4% of the global hemato oncology testing market in 2020.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2028.
  • North America is the fastest growing regional market and is projected to reach USD 2,516.4 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hemato Oncology Testing Market Companies

Name Profile # Employees HQ Website

North America hemato oncology testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.


Lymphoma was the largest segment with a revenue share of 46.88% in 2020. Horizon Databook has segmented the North America hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.


North America dominated the hemato-oncology testing market in 2020 and is expected to maintain its position during the forecast period. Increasing awareness about cancer, high disposable income, favorable reimbursement policies, and well-established healthcare infrastructure are some of the key factors boosting the regional market.

The U.S. accounted for the largest share in North America. Key factors contributing to its dominance include local presence of major market players, easy availability of advanced solutions, higher diagnosis & treatment rate of blood cancers, introduction of technologically advanced solutions, and increasing incidence of leukemia & lymphoma.

Reasons to subscribe to North America hemato oncology testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America hemato oncology testing market databook

  • Our clientele includes a mix of hemato oncology testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America hemato oncology testing market , including forecasts for subscribers. This continent databook contains high-level insights into North America hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

North America hemato oncology testing market size, by country, 2018-2028 (US$M)

North America Hemato Oncology Testing Market Outlook Share, 2020 & 2028 (US$M)

North America hemato oncology testing market size, by country, 2018-2028 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more